Clinical TrialMay 20, 2026, 04:07 PM
Eledon to Present New Clinical Data for Tegoprubart at ATC
AI Summary
Eledon Pharmaceuticals announced it will present new clinical data from its tegoprubart program at the American Transplant Congress (ATC) from June 20-24, 2026. The presentations will include updated results from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. The company will also host a conference call on June 22, 2026, to discuss the updated data.
Key Highlights
- Eledon Pharmaceuticals will present new clinical data from its tegoprubart program at the American Transplant Congress (ATC).
- Data includes updated results from the Phase 2 BESTOW clinical trial.
- New long-term data from the Phase 2 BESTOW extension study will also be presented.
- An oral presentation is scheduled for June 22, 2026, at 12:03 p.m. ET.
- A poster presentation is scheduled for June 20, 2026, from 5:45 p.m. - 6:45 p.m. ET.
- The company will host a conference call on June 22, 2026, at 8:00 a.m. ET to discuss the data.
Price Impact
More from ELDN